Renal Impairment Study of PF-06700841

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

May 4, 2022

Study Completion Date

May 4, 2022

Conditions

Healthy VolunteerRenal Impairment

Interventions

DRUG

PF-06700841

A single dose of 30 mg PF-06700841 will be administered on Day 1

Trial Locations (3)

Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami

University of Miami Division of Clinical Pharmacology, Miami

Prism Research LLC dba Nucleus Network, Saint Paul